Colon cancer is fairly easy to treat if it is recognized early. A non-invasive test developed by Ioannis Trantakis can now detect the preliminary stages of the condition.
In the U.S. alone, over one billion dollars is spent every year on the early diagnosis of colon cancer. As a result of cancer awareness campaigns, the market volume will increase significantly over the next few years. It is this market which Ioannis Trantakis is targeting. His approach, which starts at the molecular level, has enabled him to develop a non-invasive method to uncover one of the causes of cancer. Specifically, these are molecules found in food which dock onto certain genes in our DNA. These connections play an important role in the development of cancer. Trantakis’s method makes it possible to use a non-invasive procedure (i.e., without a cut or the insertion of instruments or catheters but externally) to determine whether someone belongs to the risk group; in a second step, invasive methods can then be used to search for first signs of damage – so-called predecessor lesions – and remove them in time. About his plans, Trantakis said: “Our goal is to develop and validate a kit with which the tests can be conducted in a simple procedure.”